Last Updated : September 18, 2017
Details
FilesGeneric Name:
Blinatumomab
Project Status:
Complete
Therapeutic Area:
Acute Lymphoblastic Leukemia (ALL)
Manufacturer:
Amgen Canada Inc.
Brand Name:
Blincyto (Resubmission)
Project Line:
Reimbursement Review
Project Number:
PC0097-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
38.5mcg vial
Tumour Type:
Leukemia
Indications:
Adult Acute Lymphoblastic Leukemia (ALL)
Funding Request:
For the treatment of all adult patients with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL), including those who have had one prior line of therapy (i.e., adult patients who are refractory or patients who are in first or later relapse)
Sponsor:
Amgen Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : September 18, 2017